Edgen Stock·Sep 11 2025, 20:07戻る
戻る
Takeda’s Oveporexton (TAK-861) Phase 3 Results Point to Potential for Narcolepsy Treatment
Edgen Stock·Sep 11 2025, 20:07
[1] Takeda Pharmaceutical Company Limited (TAK) Oveporexton (TAK-861) Investor Call On Phase 3 (https://seekingalpha.com/article/4820478-take ...)[2] Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025 (https://www.takeda.com/investors/events/#tab- ...)[3] Salesforce Reports Record Second Quarter Fiscal 2026 Results (https://www.businesswire.com/news/home/202509 ...)